EA201400963A1 - Фармацевтический препарат, содержащий производное дигидрохиназолина с противовирусной активностью - Google Patents

Фармацевтический препарат, содержащий производное дигидрохиназолина с противовирусной активностью

Info

Publication number
EA201400963A1
EA201400963A1 EA201400963A EA201400963A EA201400963A1 EA 201400963 A1 EA201400963 A1 EA 201400963A1 EA 201400963 A EA201400963 A EA 201400963A EA 201400963 A EA201400963 A EA 201400963A EA 201400963 A1 EA201400963 A1 EA 201400963A1
Authority
EA
Eurasian Patent Office
Prior art keywords
dihydrochinazolin
derivative
pharmaceutical preparation
preparation containing
virus activity
Prior art date
Application number
EA201400963A
Other languages
English (en)
Other versions
EA026584B1 (ru
Inventor
Керстин Паулус
Вильфрид Шваб
Доминик Грундер
Петер Ван Хогевест
Original Assignee
Аикурис Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47757622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201400963(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Аикурис Гмбх Унд Ко. Кг filed Critical Аикурис Гмбх Унд Ко. Кг
Publication of EA201400963A1 publication Critical patent/EA201400963A1/ru
Publication of EA026584B1 publication Critical patent/EA026584B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

В заявке описаны фармацевтические препараты, прежде всего предназначенные для внутривенного введения, которые содержат {8-фтор-2-[4-(3-метоксифенил)пиперазин-1-ил]-3-[2-метокси-5-(трифторметил)фенил]-3,4-дигидрохиназолин-4-ил}уксусную кислоту в комбинации по крайней мере с одним вспомогательным веществом, выбранным из циклодекстринов, лизина и аргинина, способы их получения, а также их применение для лечения и/или профилактики заболеваний, прежде всего их применения в качестве противовирусных средств, прежде всего против цитомегаловирусов.
EA201400963A 2012-02-29 2013-02-28 Фармацевтический препарат, содержащий производное дигидрохиназолина с противовирусной активностью EA026584B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102012101680A DE102012101680A1 (de) 2012-02-29 2012-02-29 Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
PCT/EP2013/054114 WO2013127970A1 (de) 2012-02-29 2013-02-28 Pharmazeutische zubereitung enthaltend ein antiviral wirksames dihydrochinazolinderivat

Publications (2)

Publication Number Publication Date
EA201400963A1 true EA201400963A1 (ru) 2015-02-27
EA026584B1 EA026584B1 (ru) 2017-04-28

Family

ID=47757622

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400963A EA026584B1 (ru) 2012-02-29 2013-02-28 Фармацевтический препарат, содержащий производное дигидрохиназолина с противовирусной активностью

Country Status (37)

Country Link
US (1) US10603384B2 (ru)
EP (3) EP4328218A3 (ru)
JP (1) JP6387486B2 (ru)
KR (1) KR102149561B1 (ru)
CN (2) CN104144678A (ru)
AU (1) AU2013224947B2 (ru)
BR (1) BR112014020946B1 (ru)
CA (1) CA2865203C (ru)
CL (1) CL2014002306A1 (ru)
CO (1) CO7061076A2 (ru)
CY (1) CY1121910T1 (ru)
DE (1) DE102012101680A1 (ru)
DK (2) DK3556350T3 (ru)
EA (1) EA026584B1 (ru)
ES (1) ES2741698T3 (ru)
FI (1) FI3556350T3 (ru)
HK (1) HK1205462A1 (ru)
HR (2) HRP20240197T1 (ru)
HU (1) HUE045949T2 (ru)
IL (1) IL234363B (ru)
IN (1) IN2014MN01892A (ru)
LT (2) LT3556350T (ru)
MA (1) MA35941B1 (ru)
ME (1) ME03448B (ru)
MX (1) MX369666B (ru)
MY (1) MY172310A (ru)
NZ (1) NZ628444A (ru)
PH (1) PH12014501937A1 (ru)
PL (2) PL2819648T3 (ru)
PT (2) PT3556350T (ru)
RS (2) RS59157B1 (ru)
SG (1) SG11201405294XA (ru)
SI (2) SI3556350T1 (ru)
TN (1) TN2014000345A1 (ru)
UA (1) UA111415C2 (ru)
WO (1) WO2013127970A1 (ru)
ZA (1) ZA201405949B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
CA2916143C (en) * 2013-06-19 2019-01-29 Aicuris Anti-Infective Cures Gmbh Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
US11864912B2 (en) 2016-06-03 2024-01-09 Atreya Innovations Private Limited Device for the detection and reliable capturing of the pulse characteristics
MY196966A (en) * 2017-03-06 2023-05-15 Everest Medicines Singapore Pte Ltd Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
UY39095A (es) 2020-02-27 2021-09-30 Aic246 Gmbh & Co Kg Composiciones farmacéuticas que comprenden acetato de 2- [(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5- (trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
UY39099A (es) 2020-02-27 2021-08-31 Aic246 Gmbh & Co Kg 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmacéuticas del mismo
CN114539085B (zh) * 2020-11-26 2023-10-20 山东诚创蓝海医药科技有限公司 一种脲基衍生物的制备
CN115403528A (zh) * 2021-05-27 2022-11-29 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
CN113880776B (zh) * 2021-11-16 2023-06-16 山东诚创蓝海医药科技有限公司 一种莱特莫韦中间体的制备方法
AR128035A1 (es) 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
CN115322157B (zh) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 来特莫韦中间体化合物及其制备方法和应用
CN115677539B (zh) * 2022-11-01 2023-10-24 南京工业大学 一种温和条件下钴催化脲基导向芳烃的高选择性单烯基化的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1242699A (en) * 1985-02-01 1988-10-04 Bristol-Myers Company Cefbuperazone and derivatives thereof
FR2585705B1 (fr) * 1985-08-05 1989-01-13 Bristol Myers Co Sels de cephalosporine et compositions injectables
JP3552240B2 (ja) * 1993-02-23 2004-08-11 第一製薬株式会社 高濃度ｔｃｆ製剤
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
JP4619545B2 (ja) * 1999-03-17 2011-01-26 アストラゼネカ アクチボラグ アミド誘導体
WO2001091751A1 (en) * 2000-05-30 2001-12-06 Novo Nordisk A/S New pharmaceutical composition and the process for its preparation
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
CA2546932A1 (en) * 2003-11-25 2005-06-09 Chiron Corporation Quinazolinone compounds as anticancer agents
EP1846410B1 (en) 2005-02-10 2009-01-21 Bristol-Myers Squibb Company Dihydroquinazolinones as 5ht modulators
DE102005027517A1 (de) * 2005-06-15 2006-12-21 Bayer Healthcare Ag Verfahren zur Herstellung von Dihydrochinazolinen
US8743287B2 (en) * 2009-07-24 2014-06-03 Broadcom Corporation Method and system for mitigating motion trail artifacts and improving low contrast contours in temporal filtering based noise reduction

Also Published As

Publication number Publication date
MX2014010364A (es) 2014-12-05
WO2013127970A1 (de) 2013-09-06
ME03448B (me) 2020-01-20
KR102149561B1 (ko) 2020-08-31
LT2819648T (lt) 2019-09-10
TN2014000345A1 (en) 2015-12-21
SG11201405294XA (en) 2014-11-27
CA2865203A1 (en) 2013-09-06
AU2013224947B2 (en) 2017-06-29
PT2819648T (pt) 2019-09-05
EP3556350B1 (de) 2024-01-10
PT3556350T (pt) 2024-02-15
EP3556350A1 (de) 2019-10-23
US10603384B2 (en) 2020-03-31
PL2819648T3 (pl) 2019-10-31
DK3556350T3 (da) 2024-02-12
LT3556350T (lt) 2024-02-26
MA35941B1 (fr) 2014-12-01
ZA201405949B (en) 2021-07-28
JP6387486B2 (ja) 2018-09-12
HRP20240197T1 (hr) 2024-04-26
HRP20191369T1 (hr) 2019-11-01
EP4328218A3 (de) 2024-04-10
SI3556350T1 (sl) 2024-03-29
BR112014020946B1 (pt) 2022-04-05
IN2014MN01892A (ru) 2015-07-10
DE102012101680A1 (de) 2013-08-29
RS59157B1 (sr) 2019-10-31
EP4328218A2 (de) 2024-02-28
US20150133461A1 (en) 2015-05-14
CN104144678A (zh) 2014-11-12
NZ628444A (en) 2016-07-29
HK1205462A1 (en) 2015-12-18
CL2014002306A1 (es) 2014-11-28
RS65137B1 (sr) 2024-02-29
FI3556350T3 (fi) 2024-02-14
EP2819648A1 (de) 2015-01-07
PH12014501937A1 (en) 2014-11-24
MX369666B (es) 2019-11-14
IL234363B (en) 2020-04-30
CA2865203C (en) 2019-11-05
BR112014020946A2 (ru) 2017-06-20
CN110433166A (zh) 2019-11-12
EA026584B1 (ru) 2017-04-28
KR20140130683A (ko) 2014-11-11
PL3556350T3 (pl) 2024-05-06
MY172310A (en) 2019-11-21
JP2015508801A (ja) 2015-03-23
SI2819648T1 (sl) 2019-10-30
ES2741698T3 (es) 2020-02-12
HUE045949T2 (hu) 2020-01-28
CO7061076A2 (es) 2014-09-19
UA111415C2 (uk) 2016-04-25
DK2819648T3 (da) 2019-08-26
CY1121910T1 (el) 2020-10-14
EP2819648B1 (de) 2019-05-29
AU2013224947A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
EA201400963A1 (ru) Фармацевтический препарат, содержащий производное дигидрохиназолина с противовирусной активностью
CY1122291T1 (el) Αναστολeις ιικου αναδιπλασιασμου
EA201791916A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
CY1120049T1 (el) (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i
BR112014032699A2 (pt) métodos de tratamento de síndrome metabólica pediátrica
CY1119058T1 (el) Ενωσεις ιμιδαζοπυρρολιδινονης
EA201500448A1 (ru) Гуанидиновое соединение
EA201401281A1 (ru) D-аминокислотные химические соединения для лечения заболеваний печени
BR112013030894A2 (pt) moduladores do sistema imune
EA201590457A1 (ru) Сульфамоил-ариламиды и их применение в качестве лекарственных препаратов для лечения гепатита b
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
UA117103C2 (uk) Сполука, яка має активність агоніста глюкагону
EA201490419A1 (ru) Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания
EA201301173A1 (ru) Клональные штаммы аттенуированных вакцинирующих вирусов и способы их использования
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний
EA201490377A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата
EA201490254A1 (ru) Комбинированное лечение гепатита с
MX2014004814A (es) Compuestos y metodos para mejorar las respuestas inmunes innatas.
BR112015010396A2 (pt) terapia de combinação
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MX2015013649A (es) Inhibidores novedosos de la replicación viral.
EA201490045A1 (ru) Дейтерированные 1-пиперазино-3-фенилинданы, применяемые для лечения шизофрении
GEP20156332B (en) Pyrazoles as crth2 antagonists
BR112012019515A2 (pt) indutor de continuação de leitura, e agente terapêutico para doenças genéticas do tipo de mutações anti-senso

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment